Hanke T, Neumann V C, Blanchard T J, Sweeney P, Hill A V, Smith G L, McMichael A
Molecular Immunology Group, Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, Headington, UK.
Vaccine. 1999 Feb 12;17(6):589-96. doi: 10.1016/s0264-410x(98)00238-2.
Reliable and effective induction of cytotoxic T-lymphocytes (CTL) is one of the prime objectives of vaccine research. Previously, novel HIV vaccine candidates were constructed as a string of CTL epitopes (20 human, 3 macaque and 1 mouse) delivered using a DNA vector [Hanke T, Schneider J, Gilbert SG, Hill AVS, McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998;16:426-435.] or modified vaccinia Ankara (MVA [Hanke T, Blanchard TJ, Schneider J, Ogg GS, Tan R, Becker MSC, Gilbert SG, Hill AVS, Smith GL, McMichael A. Immunogenicities of intravenous and intramuscular administrations of MVA-based multi-CTL epitope vaccine for HIV in mice. J Gen Virol 1998;79:83-90.]), i.e. vaccine vehicles acceptable for use in humans. In mice, a single intramuscular (i.m.) needle injection of either vaccine alone elicited good CTL responses. Here, it is demonstrated that the multi-epitope DNA also induced CTL when delivered intradermally using the Accell gene gun. The CTL responses increased after re-immunization and after three deliveries were comparable to those induced by a single i.m. injection. Recent evidence indicates that combining routes and vaccine vehicles enhances the immunogenicity of vaccine-delivered or -encoded antigens. Here, it is shown that administration of DNA by an i.m. priming/gene gun boosting more efficiently induced CTL than gene gun priming/i.m. boosting. A similar increment was obtained by sequential vaccinations using a gene gun-delivered DNA followed by recombinant MVA. Thus particular sequences of routes or vaccine vehicles rather than simple prime-boost delivery of a single vaccine is critical for an effective elicitation of CTL.
可靠且有效地诱导细胞毒性T淋巴细胞(CTL)是疫苗研究的主要目标之一。此前,新型HIV疫苗候选物被构建为由DNA载体递送的一串CTL表位(20个人类、3个猕猴和1个小鼠的表位)[汉克T,施奈德J,吉尔伯特SG,希尔AVS,麦克迈克尔A。用于HIV和恶性疟原虫的DNA多CTL表位疫苗:在小鼠中的免疫原性。疫苗1998;16:426 - 435。]或改良痘苗安卡拉病毒(MVA[汉克T,布兰查德TJ,施奈德J,奥格GS,谭R,贝克尔MSC,吉尔伯特SG,希尔AVS,史密斯GL,麦克迈克尔A。基于MVA的HIV多CTL表位疫苗在小鼠中静脉内和肌肉内给药的免疫原性。普通病毒学杂志1998;79:83 - 90。]),即人类可接受使用的疫苗载体。在小鼠中,单独单次肌肉内(i.m.)针注射任何一种疫苗均可引发良好的CTL反应。在此证明,当使用Accell基因枪皮内递送时,多表位DNA也能诱导CTL。再次免疫后CTL反应增强,三次递送后的反应与单次i.m.注射诱导的反应相当。最近的证据表明,联合使用不同途径和疫苗载体可增强疫苗递送或编码抗原的免疫原性。在此表明,i.m.初免/基因枪加强免疫比基因枪初免/i.m.加强免疫更有效地诱导CTL。通过使用基因枪递送的DNA随后接种重组MVA进行序贯接种也获得了类似的增强效果。因此,特定的途径或疫苗载体顺序而非单一疫苗的简单初免 - 加强给药对于有效诱导CTL至关重要。